Atossa Genetics Inc (NASDAQ:ATOS) a clinical-stage pharmaceutical firm developing novel delivery methods and therapeutics for breast cancer and other breast problems, reported that the Ernest Mario School of Pharmacy at Rutgers, intends to plan a study using company’s intraductal microcatheter technology.
The details
The Rutgers researchers consider that directly administering medications into the breast duct, by putting microcatheters into the nipple, marks as a better option than systemic administration, as the medications will be directly administered to the tissue. The Rutgers plan utilizes an innovative directed delivery mechanism constituted of nanoscale pharmaceutical carriers full of single drugs. The long-term objective of the research plan is to advance a locally administered drug delivery mechanism that selectively targets and offers pathway-specific targeting therapeutics to remove cancer stem-like cells and breast cancer cells while sparing normal breast cells.
Steven Quay, MD, PhD, the President and CEO of Atossa, expressed that they are thrilled that a major research institution such as Rutgers understands the prospective advantage of their microcatheter technology. The company entirely supports additional research using their patented microcatheter technology.
The Rutgers plan is in the research and development stage and has not been permitted by the FDA or any other regulatory firm. Studies demonstrating efficacy and safety, among other things, and regulatory nods will be needed before commercialization.
Earlier Atossa reported that a new program utilizing Chimeric Antigen Receptor Therapy, it intends to utilize its intraductal microcatheter technology to offer CAR-T cells into the breast ducts for the prospective intended treatment of breast cancer.
The company’s novel approach utilizes its intraductal microcatheter know-how for the potential transpapillary, for T-cells delivery that have been genetically changed to attack breast cancer cells. Atossa considers this method has numerous potential advantages: lowered toxicity by confining systemic exposure of the T-cells; enhanced efficacy by putting the T-cells in direct contact with the aimed ductal epithelial cells that are facing malignant transformation; and others.
